News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Franchini Indrani Lall
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/01/2023 |
4
| Franchini Indrani Lall (EVP, CLO & Secretary) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 2,632 restricted stock units
@ $0
Granted 5,449 options to buy
@ $190.01, valued at
$1M
|
|
| 02/03/2023 |
4
| Franchini Indrani Lall (EVP, CLO & Secretary) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Sold 77 shares
@ $223.97, valued at
$17.2k
Sold 1,007 shares
@ $225.8, valued at
$227.4k
Sold 586 shares
@ $226.62, valued at
$132.8k
Sold 5 shares
@ $227.38, valued at
$1.1k
Exercised 5,175 restricted stock units
@ $0 |
|
| 02/09/2022 |
4
| Franchini Indrani Lall (EVP, CLO & Secretary) has filed a Form 4 on ALNYLAM PHARMACEUTICALS, INC.|
Txns:
| Granted 15,525 restricted stock units
@ $0
Granted 29,182 options to buy
@ $144.93, valued at
$4.2M
|
|
| 02/09/2022 |
3
| Franchini Indrani Lall (EVP, CLO & Secretary) has filed a Form 3 on ALNYLAM PHARMACEUTICALS, INC. |
| 07/23/2021 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Disposed/sold 116,075 shares
@ $0
Disposed/sold 25,165 options to buy
@ $100.14, valued at
$2.5M
|
|
| 07/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/18/2020 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Granted 37,965 shares
@ $0
Paid exercise price by delivering 16,925 shares
@ $157.96, valued at
$2.7M
Paid exercise price by delivering 2,913 shares
@ $157.96, valued at
$460.1k
|
|
| 06/09/2020 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,403 shares
@ $114.61, valued at
$160.8k
Sold 5,420 shares
@ $114.61, valued at
$621.2k
Sold 1,433 shares
@ $115, valued at
$164.8k
|
|
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/11/2019 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 1,404 shares
@ $118.61, valued at
$166.5k
|
|
| 03/05/2019 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Granted 8,250 shares
@ $0 |
|
| 03/04/2019 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Paid exercise price by delivering 625 shares
@ $132.93, valued at
$83.1k
|
|
| 02/11/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/30/2018 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS, INC.|
Txns:
| Sold 2,605 shares
@ $118.13, valued at
$307.7k
|
|
| 06/12/2018 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Sold 1,466 shares
@ $118.53, valued at
$173.8k
|
|
| 03/02/2018 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Granted 8,344 shares
@ $0 |
|
| 02/08/2018 |
4
| Franchini Indrani Lall (EVP, Chief Compliance Officer) has filed a Form 4 on ALEXION PHARMACEUTICALS INC|
Txns:
| Granted 13,908 shares
@ $0
Sold 1,459 shares
@ $116.31, valued at
$169.7k
|
|
| 06/09/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 06/09/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities |
|
|